TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05384119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (AI)
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (AI)
Description: Oral tablet
Study: NCT06362954

Intervention type: OTHER
Intervention: Assessment
Description: Chedoke-McMaster Stroke Assessment (CMSA), Modified Ashworth Scale (MAS), Near-Infrared Spectroscopy (NIRS), 6-Minute Walk Test (6MWT), Stair Climbing Test (SCT), Adipose Tissue Thickness
Study: NCT04775563

Intervention type: OTHER
Intervention: COVID-19 vaccine hesitancy scale in rheumatic diseases
Description: The instrument was developed by Freeman et al, prior to its application, translation, cultural adaptation, and validation were performed.

Intervention type: OTHER
Intervention: COVID-19 vaccine hesitancy associated factors
Description: The instrument includes questions about the doctor-patient relationship, perception of the COVID-19 vaccine, perception of risk of COVID-19 infection, perception of the severity of the pandemic in Mexico, perception of the severity of their rheumatic disease, perception of the control of comorbidities, perception of the intensity of the immunosuppressive treatment, positioning of the patient towards vaccines for COVID-19
Study: NCT06097884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Main study intervention-Salt substitute
Description: replacing regular salt with salt substitute in school meals

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Main study control-Usual salt
Description: Use usual salt in school meals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ancillary study intervention-Meal trays
Description: Replacing bowls with trays in school cafeteria

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ancillary study control-Bowls
Description: Use bowls in school cafeteria
Study: NCT05487963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib Citrate
Description: Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo ointment
Description: Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
Study: NCT05778812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Sleep
Description: Daily lessons about sleep and skills that can help with sleep. Participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach, for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Path to Better Sleep
Description: Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
Study: NCT05137392

Intervention type: OTHER
Group type: OTHER
Intervention: oral hygiene instruction
Description: The treatment process is identical for both test and control groups except for the methods of oral hygiene instructions. In the control group, the participants will receive the following oral hygiene instructions at completion of debridement, at week-1 and week-3. In the test group, apart from the standard oral hygiene instructions at completion of debridement, at week-1 and week-3 , additional analysis of brushing data and provision of targeted brief interventions will be provided on a daily basis for the first week, 3 times/week until week 6 and once a week thereafter until 6 months after the debridement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral hygiene instruction
Description: The treatment process is identical for both test and control groups except for the methods of oral hygiene instructions. In the control group, the participants will receive the following oral hygiene instructions at completion of debridement, at week-1 and week-3. In the test group, apart from the standard oral hygiene instructions at completion of debridement, at week-1 and week-3 , additional analysis of brushing data and provision of targeted brief interventions will be provided on a daily basis for the first week, 3 times/week until week 6 and once a week thereafter until 6 months after the debridement.
Study: NCT05359744

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Performance testing
Description: Performance testing on a bicycle ergometer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Performance testing
Description: Performance testing on a bicycle ergometer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Performance testing
Description: Performance testing on a bicycle ergometer.
Study: NCT04550624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: 200mg IV on day 1 of each cycle
Study: NCT03987282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care (EUC)
Description: Provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced usual care (EUC)
Description: Provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-based counseling
Description: Peer-based counseling intervention focused on behavioral skills and strategies that patients can learn and master to achieve uninterrupted, long-term ART treatment participation while continuing OUD recovery through MMT
Study: NCT04899674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elontril
Description: Elontril
Study: NCT04550624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate
Description: 20mg PO daily days 1-21 of each cycle
Study: NCT05497089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temelimab 54mg/kg
Description: Temelimab 54mg/kg will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
Study: NCT05029141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAHAG regimen
Description: Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial.
Study: NCT05384119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Oral tablet
Study: NCT04899674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: BI 1358894
Study: NCT05029141

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo regimen
Description: Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial.
Study: NCT05384119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Oral tablet
Study: NCT05149989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proning Pillow System
Description: Participants will be asked to lie on the proning pillows in prone position for no more than 5 minutes. Each participant will then be asked to lie on standard hospital pillows for no more than 5 minutes.
Study: NCT06566235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted DBT-A-ST group
Description: The culturally adapted DBT-A-ST consists of 15 weekly group sessions, each lasting 120 minutes, including a 10-minute break. It maintains the core elements of standard DBT-A, including its philosophical foundation and treatment strategies.~Therapists focus on teaching DBT skills through various methods such as modeling, structured behavioral rehearsals, and feedback. Each session begins with a 40-minute group mindfulness exercise and homework review, followed by 60 minutes dedicated to skill-specific didactics and experiential activities, concluding with a 10-minute homework assignment. Two group leaders facilitate the sessions, and participants track their skill usage daily with diary cards, which are reviewed weekly.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Activities-based support group (ASG)
Description: ASG, based on principles of client-centered supportive therapy, is widely used by occupational therapists in mental health settings. ASG therapists aim to foster a sense of belongingness, maintain unconditional positive regard, provide empathy, psychoeducational and a treatment structure. Two group leaders held the sessions, teaching DBT skills and using cognitive behavioral strategies are prohibited. Each session starts with a review of their experiences over the last week (30 min), a support-building activity (30 min), and ends with an open group discussion about topics participants choose each week (50 min). For homework, participants will be asked to think about issues discussed and to track daily social support on diary cards.
Study: NCT06568874

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) Therapy
Description: Intervention: Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment
Description: Intervention: Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period.
Study: NCT06568588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745
Description: 250 mg three times a day for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745
Description: 250 mg three times a day for 4 months
Study: NCT05691218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nebulization
Description: Beta-2 adrenergic agonist administred by standrad nebulization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A - Vibrating mesh nebulization
Description: Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen
Description: High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device.~HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device
Study: NCT05106179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol Pill
Description: Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol Pill
Description: Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.
Study: NCT05057416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Adherence
Description: Our current study will compare three exercise groups which will all vary in intensity. Participants will be randomly assigned to one of the three groups. Two groups will be assigned to high intensity bouts of exercise with an active rest between, and one group will perform moderate intensity continuous training without resting. All groups will exercise for 20 minutes. Exercise adherence and it will be measured by a self-report online Google Document.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Adherence
Description: Our current study will compare three exercise groups which will all vary in intensity. Participants will be randomly assigned to one of the three groups. Two groups will be assigned to high intensity bouts of exercise with an active rest between, and one group will perform moderate intensity continuous training without resting. All groups will exercise for 20 minutes. Exercise adherence and it will be measured by a self-report online Google Document.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Adherence
Description: Our current study will compare three exercise groups which will all vary in intensity. Participants will be randomly assigned to one of the three groups. Two groups will be assigned to high intensity bouts of exercise with an active rest between, and one group will perform moderate intensity continuous training without resting. All groups will exercise for 20 minutes. Exercise adherence and it will be measured by a self-report online Google Document.
Study: NCT04679233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription aerobic exercise
Description: high intensity interval training, 5 weeks, 2 sessions/week - supervised by a clinician.
Study: NCT06288516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg/ml
Description: Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks
Study: NCT04587934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRes Warmer with ResusView
Description: Rapid heart rate display utilizing optimized ECG algorithm in iRes Warmer in babies delivered between 23+0 and 32+6 weeks estimated gestational age
Study: NCT05940571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-362
Description: Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-362
Description: Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-362
Description: Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-362
Description: Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
Study: NCT04946669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept is a CTLA-4 fusion protein that inhibits T cell activation by competitively binding to CD80/CD86 and blocking the second signal. To date, Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases (refractory rheumatoid arthritis, juvenile idiopathic arthritis, and active psoriatic arthritis). The international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports. However, to date, there is no relevant report or clinical study registration information of Abatacept in the treatment of dermatomyositis.
Study: NCT04587934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iRes Warmer without ResusView
Description: Electrocardiogram monitoring using external ECG monitor in babies delivered between 23+0 and 32+6 weeks estimated gestational age
Study: NCT06247033

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tibial Nerve Stimulation with TENS device
Description: Tibial nerve stimulation was applied with TENS device transcutaneously and electrodes were positioned in medial part of the ankle. Negative transcutaneous electrode was positioned 3 centimeter posteriorly to the medial malleol. And positive transcutaneous electrode was positioned 10 centimeter above the negative electrode.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pelvic muscle training exercise with bladder training
Description: Control group was followed with sham tibial nerve stimulation, which were performed by after starting electric current with TENS device, current were decreased and completely shut off. Sham stimulation was also applied for 6 weeks, 2 times in a week, 30 minutes. All patients were followed for PFTE and BT according to given standard schedule.
Study: NCT06366971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Patient Education
Description: The patient education will be given through a brochure and the content of the education included an exercise training consisting of simple exercises for lumbar stabilization (supine bridge, cat-camel, and lumbar stretching) and the participants will be asked to perform these exercises in 3 sets of 10 repetitions 3 days a week for 6-weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Patient Education
Description: The patient education will be given through a brochure and the content of the education included an exercise training consisting of simple exercises for lumbar stabilization (supine bridge, cat-camel, and lumbar stretching) and the participants will be asked to perform these exercises in 3 sets of 10 repetitions 3 days a week for 6-weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Pelvic Proprioceptive Neuromuscular Facilitation Techniques Training
Description: The content of the pelvic proprioceptive neuromuscular facilitation techniques training will include the application of the anterior depression pattern with the rhythmic initiation technique and the application of the posterior elevation pattern with the contract-relax stretch technique. All PNF techniques will be performed in 3 sets of 10 to 12 repetitions. The pelvic proprioceptive neuromuscular facilitation techniques training will be delivered face to face 3 days a week for 6 weeks by an experienced and trained physiotherapist.
Study: NCT05007652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN125(pegfilgrastim), PLR001(plerixafor)
Description: 7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN125(pegfilgrastim), PLR001(plerixafor)
Description: 7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRN8601(filgrastim), PLR001(plerixafor)
Description: 400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.